
Gastrointestinal Drug Market Size Was Valued at USD 53760 Million in 2023 and is Projected to Reach USD 87040 Million by 2032, Growing at a CAGR of 5.5% From 2024-2032.
A Gastrointestinal drug that is used for the functional disorders of the Gastrointestinal system like controlling and getting relief from gastric acidity, regulating gastrointestinal motility, Irritable bowel syndrome, Chronic bloating, diarrhea, water flow, and improving digestion. It is used to treat Gastroesophageal reflux disease and Peptic ulcers by using Medications such as proton pump inhibitors, H2 receptor blockers, and antacids which are used to reduce and heal stomach acid production proton pump inhibitors, these are the most powerful antisecretory drugs available because they bind to the H+K+ ATP-ase, which is the final step in the production of acid by the gastric parietal cell and they are rapidly replaced the less potent H2-receptor antagonists.
They are used to treat irritable bowel syndrome by using Different types of medications like antispasmodics, laxatives, and antidiarrheals, that are prescribed to control symptoms like abdominal pain, bloating, cramping, bloating, and irregular bowel movements associated with the intestine. They are also used to treat Inflammatory Bowel Diseases like Crohn's disease and ulcerative colitis by using immunosuppressants, corticosteroids, anti-inflammatory drugs, and biologics which are used to reduce the inflammation and control the symptoms.They are used for the treatment of Diarrhea with the use of medications like loperamide, which are used to slow down bowel movements and reduce the frequency in cases of acute or chronic diarrhea. They are used to control Nausea and Vomiting by the application of Antiemetic medications that can help to relieve nausea and vomiting which are caused by various factors like motion sickness, chemotherapy, and postoperative recovery.
“AbbVie Inc. (USA), Pfizer Inc. (USA), Takeda Pharmaceuticals (Japan), Gilead Sciences, Inc (USA), Ironwood Pharmaceuticals, Inc. (USA), Bausch Health Companies Inc. (Canada), AzurRx BioPharma, Inc. (USA), AstraZeneca (UK), Sanofi (France), GlaxoSmithKline (GSK) (UK), Novartis (Switzerland), Boehringer Ingelheim (Germany), Bayer (Germany), Eli Lilly and Company (USA), Theravance Biopharma (USA), Otsuka Pharmaceutical (Japan), UCB (Belgium), Norgine (UK), Ferring Pharmaceuticals (Switzerland), Recordati (Italy), Seres Therapeutics (USA), Roche (Switzerland), AstraZeneca PLC (UK), Cipla (India), Bristol-Myers Squibb Company (USA) and Other Active Players.”
The gastrointestinal Drug Market is Segmented on the basis of Drug Class, Application, Route of Administration, Age Group, and Distribution Channel.
Gastrointestinal Drug Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 53760 Mn. |
Forecast Period 2024-32 CAGR: |
5.5 % |
Market Size in 2032: |
USD 87040 Mn. |
Segments Covered: |
By Drug Class |
|
|
By Application |
|
||
By Route of Administration |
|
||
By Age Group |
|
||
By Distribution Channel |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Gastrointestinal Drug Market by By Drug Class
4.1 Gastrointestinal Drug Market Snapshot and Growth Engine
4.2 Gastrointestinal Drug Market Overview
4.3 Acid Neutralizers
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in
The forecast period in the Gastrointestinal Drug Market research report is 2024-2032.
AbbVie Inc. (USA), Pfizer Inc. (USA), Takeda Pharmaceuticals (Japan), Gilead Sciences, Inc (USA), Ironwood Pharmaceuticals, Inc. (USA), Bausch Health Companies Inc. (Canada), AzurRx BioPharma, Inc. (USA), AstraZeneca (UK), Sanofi (France), GlaxoSmithKline (GSK) (UK), Novartis (Switzerland), Boehringer Ingelheim (Germany), Bayer (Germany), Eli Lilly and Company (USA), Theravance Biopharma (USA), Otsuka Pharmaceutical (Japan), UCB (Belgium), Norgine (UK), Ferring Pharmaceuticals (Switzerland), Recordati (Italy), Seres Therapeutics (USA), Roche (Switzerland), AstraZeneca PLC (UK), Cipla (India), Bristol-Myers Squibb Company (USA) and Other Active Players.
The Gastrointestinal Drug Market is segmented into Drug Class, Application, Route of Administration, Age Group, Distribution Channel, Segment6, and region. By Drug Class, the market is categorized into Acid Neutralizers, Anti-inflammatory, Biologics, Antidiarrheal & Laxatives, Antiemetic & Antinauseant, And Others {Antispasmodics, Prokinetics}. By Application, the market is categorized into Inflammatory Ulcerative Colitis, Irritable Bowel Syndrome, Crohn’s Disease, Celiac Disease, Gastroenteritis, And Others {Nausea, Vomiting}. By Route of Administration, the market is categorized into Rectal, Oral, and Parenteral. By Age Group, the market is categorized into adult and pediatric. By Distribution Channel, The Market Is Categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
A drug that is used for the functional disorders of the Gastrointestinal system like controlling and getting relieved from gastric acidity, regulating gastrointestinal motility, Irritable bowel syndrome, Chronic bloating, diarrhea, water flow, and improving digestion.
Gastrointestinal Drug Market Size Was Valued at USD 53760 Million in 2023 and is Projected to Reach USD 87040 Million by 2032, Growing at a CAGR of 5.5% From 2024-2032.